[
  {
    "question": "What testing is required prior to RETU admission for PE patients?",
    "answer": "Required testing includes: CBC, Basic Metabolic Panel, PT/INR and aPTT, Troponin and BNP, CT Angio Chest (or V/Q Scan), Doppler US results (as indicated), and pregnancy test (appropriate age female).",
    "source": "RETU PE Pathway.pdf",
    "category": "protocol"
  },
  {
    "question": "What patients with PE are not appropriate for RETU?",
    "answer": "Not appropriate for RETU: hypoxemia, vital sign abnormality (tachycardia, hypotension, or orthostatic vital sign changes), history of chronic cardiopulmonary disease (CHF, CAD, COPD), cardiac arrhythmias of immediate concern, RV dysfunction/strain (by echo or EKG), positive cardiac biomarker (positive trop or elevated BNP), patient at high risk for hemorrhage on anticoagulation (active bleeding), limb-threatening thrombosis, thrombolysis or pharmacomechanical thrombectomy needed, IVC filter placement needed, pregnancy with delivery planned, contraindication to outpatient use of anticoagulation medication.",
    "source": "RETU PE Pathway.pdf",
    "category": "criteria"
  },
  {
    "question": "What should be the examination focus for PE patients in RETU?",
    "answer": "Examination focus should be: Cardiopulmonary and Vascular systems.",
    "source": "RETU PE Pathway.pdf",
    "category": "protocol"
  },
  {
    "question": "What initial testing should be performed for PE patients in RETU?",
    "answer": "Initial testing includes: Labs - CBC, BMP, PT/PTT (others as clinically indicated); Imaging - Transthoracic echocardiogram.",
    "source": "RETU PE Pathway.pdf",
    "category": "protocol"
  },
  {
    "question": "What monitoring is required for PE patients in RETU?",
    "answer": "Monitoring includes: vital signs q4h, telemetry, and continuous pulse oximetry (as indicated).",
    "source": "RETU PE Pathway.pdf",
    "category": "protocol"
  },
  {
    "question": "What are the preferred anticoagulation options for PE patients?",
    "answer": "DOACs (Direct Oral Anticoagulants) are preferred if no contraindication. Options include Rivaroxaban 15mg PO bid x21 days or Apixaban 10mg PO bid x7 days.",
    "source": "RETU PE Pathway.pdf",
    "category": "dosage"
  },
  {
    "question": "What is the dosing for enoxaparin in PE patients?",
    "answer": "Enoxaparin dosing: 1 mg/kg SC q12h, or alternatively 1.5 mg/kg SC daily.",
    "source": "RETU PE Pathway.pdf",
    "category": "dosage"
  },
  {
    "question": "What is the warfarin dosing for PE patients?",
    "answer": "Warfarin: 2-5mg PO daily on day 1-2 of parenteral anticoagulation.",
    "source": "RETU PE Pathway.pdf",
    "category": "dosage"
  },
  {
    "question": "What should be ensured when prescribing DOACs for PE patients?",
    "answer": "Ensure insurance can fill medication by calling pharmacy after prescribing or involving social work.",
    "source": "RETU PE Pathway.pdf",
    "category": "protocol"
  },
  {
    "question": "What should be ensured when prescribing enoxaparin for PE patients?",
    "answer": "Ensure patient or family member is comfortable with self-injecting. Place nursing communication for teaching if on enoxaparin.",
    "source": "RETU PE Pathway.pdf",
    "category": "protocol"
  },
  {
    "question": "What follow-up is needed for warfarin therapy in PE patients?",
    "answer": "Discharge with INR check in 2 days if on warfarin.",
    "source": "RETU PE Pathway.pdf",
    "category": "protocol"
  },
  {
    "question": "What are the discharge criteria from RETU for PE patients?",
    "answer": "Discharge criteria include: no deterioration in clinical status, no development of criteria for admission (as per exclusion criteria), acceptable vital signs, pain absent or managed, and outpatient anticoagulation plan established.",
    "source": "RETU PE Pathway.pdf",
    "category": "criteria"
  },
  {
    "question": "What are the admission criteria for PE patients?",
    "answer": "Admission criteria include: RV dysfunction found on echocardiogram, unstable vital signs/other deterioration of clinical status, anticoagulation not tolerated (bleeding, allergic reaction), unable to satisfy follow-up requirements, unsafe home environment/inability to adhere as determined by social work/case management, or intractable pain.",
    "source": "RETU PE Pathway.pdf",
    "category": "criteria"
  },
  {
    "question": "When should RV dysfunction be assessed in PE patients?",
    "answer": "RV dysfunction should be assessed with transthoracic echocardiogram as part of initial testing in RETU.",
    "source": "RETU PE Pathway.pdf",
    "category": "protocol"
  }
]